Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update
August 09, 2019 08:00 ET
|
VBI Vaccines, Inc.
Positive top-line data from PROTECT Phase 3 for Sci-B-Vac®, trivalent hepatitis B vaccine, announced June 2019 – top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019ASCO...
VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 01, 2019 08:00 ET
|
VBI Vaccines, Inc.
All four lead pipeline programs progressing towards expected clinical milestones in 2019Gearing up for top-line data from the pivotal Phase 3 study of Sci-B-Vac®, VBI’s trivalent hepatitis B vaccine,...
VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop
April 03, 2019 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference
March 18, 2019 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
February 25, 2019 08:00 ET
|
VBI Vaccines, Inc.
Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the studyLicense and...
VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate
December 20, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update
November 09, 2018 07:00 ET
|
VBI Vaccines, Inc.
-- Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively -- -- Encouraging early immunologic data observed in Phase 1/2a study of...
VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018
October 02, 2018 08:00 ET
|
VBI Vaccines, Inc.
Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PDT ...
VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards
September 26, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate Update
July 26, 2018 07:00 ET
|
VBI Vaccines, Inc.
-- Pivotal Phase 3 program for Sci-B-Vac® Hepatitis B vaccine continues to advance towards topline data expected mid-year 2019 -- -- Positive safety and immunogenicity data from Phase 1 study of...